



SDM

WFH SHARED DECISION
MAKING TOOL



REFERENCES

REVIEW ARTICLES

Krumb, E. and Hermans, C. [Living with a “hemophilia-free mind” - The new ambition of hemophilia care?](#) *Res Pract Thrombosis Haemostasis*; 2021; 5, e12567.

Srivastava, A et al. [WFH Guidelines for the Management of Hemophilia](#), 3rd edition. *Haemophilia* 2020; 26, 1-158.

Weyand AC, Pipe SW. [New therapies for hemophilia](#). *Blood* 2019; 133:389-398.

SHL & EHL FACTOR THERAPY

Approved SHL Products for Hemophilia A

ADVATE	FDA	EMA	Health Canada
Kogenate FS	FDA		
KOVALTRY	FDA	EMA	
Novoeight	FDA	EMA	
NUWIQ	FDA	EMA	Health Canada
XYNTHA/ReFacto AF	FDA	EMA	Health Canada

Approved EHL Products for Hemophilia A

ADYNOVATE/ADYNOVI	FDA	EMA	Health Canada
ALTUVIIIIO	FDA		
ELOCTATE/Elocta	FDA	EMA	Health Canada
ESPEROCT	FDA	EMA	Health Canada
JIVI	FDA	EMA	Health Canada

Approved SHL Products for Hemophilia B

BeneFIX	FDA	EMA	Health Canada
IXINITY	FDA		
RIXUBIS	FDA	EMA	Health Canada

Approved EHL Products for Hemophilia B

ALPROLIX	FDA	EMA	Health Canada
IDELVION	FDA	EMA	Health Canada
REBINYN/Refixia	FDA	EMA	Health Canada



BISPECIFIC ANTIBODY THERAPY

Approved Products

HEMLIBRA (Emicizumab)

[FDA](#)

[EMA](#)

[Health Canada](#)

Phase 3 Studies

Ongoing Phase 3 Studies for Mim8: NCT05053139, NCT05306418, NCT05685238, and NCT05878938.

HEMOSTATIC REBALANCING THERAPY

Approved Products

Alhemo (Concizumab)

[Health Canada](#)

Phase 3 Studies

Young G et al. [Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors \(ATLAS-INH\): a multicentre, open-label, randomised phase 3 trial](#). *Lancet* 2023; 401:1427-1437.

Srivastava, A et al. [Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors \(ATLAS-A/B\): a multicentre, open-label, randomised, phase 3 trial](#). *Lancet Haematol.* 2023; 10, e322-e332.

Pfizer. [Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial](#). May 30, 2023.

GENE THERAPY GENERAL

Konkle BA et al. [World Federation of Hemophilia Gene Therapy Registry](#). *Haemophilia* 2020;26:563-564.

Miesbach W, Klamroth R. [The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients](#). *Patient Prefer Adherence* 2020; 14:767-770.

Pierce GF, Iorio A. [Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes](#). *Haemophilia* 2018; 24 Suppl 6:60-67.

Wang M et al. [The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making](#). *Patient Prefer Adherence* 2022; 16:1439-1447.

GENE THERAPY FOR HEMOPHILIA A

Approved Products

ROCTAVIAN

[FDA](#)

[EMA](#)

Key Clinical Studies

Mahlangu J *et al.* [Two-Year Outcomes of Valoctocogene Roxaparovec Therapy for Hemophilia A](#). *N Engl J Med* 2023; 388:694-705.

Ozelo MC *et al.* [Valoctocogene Roxaparovec Gene Therapy for Hemophilia A](#). *N Engl J Med* 2022; 386:1013-1025.

GENE THERAPY FOR HEMOPHILIA B

Approved Products

HEMGENIX

[FDA](#)

[EMA](#)

Key Clinical Studies

Pipe SW *et al.* [Gene Therapy with Etranacogene Dezaparovec for Hemophilia B](#). *N Engl J Med* 2023; 388:706-718.